Genomic signature of colon cancer may individualize treatment
Monday, November 24, 2008 - 18:21
in Health & Medicine
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.